A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Part of paid clinical trials in Las Vegas, Nevada.

Sponsor
Corxel Pharmaceuticals
Study ID
NCT07652047
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Obesity & Overweight

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • CX11 — DRUG
    CX11 tablets administered orally once daily (QD) with meals
  • Placebo — OTHER
    Matching placebo tablets administered orally once daily (QD) with meals
  • CX11 — DRUG
    CX11 tablets administered orally once daily (QD) with high fat, high calorie meal

Study Details

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Key Dates

Start date
May 11, 2026
Status verified
Jun 2026
Primary completion
Mar 31, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo group
  • Experimental: Group A
  • Experimental: Group B
  • Experimental: Group C

Primary Outcome Measure

Percentage change in body weight from baseline [ Time Frame: Week 26 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Corxel Investigational siteLas VegasNevada89113
Study Director
[email protected]
201-268-3723
Corxel Investigational SiteAustinTexas78744
Study Director
[email protected]
201-268-3723

Find similar trials in Las Vegas, NV

By research site
Corxel Investigational site· Las Vegas, NVCorxel Investigational Site· Austin, TX

Related Studies